Pankreasın Nöroendokrin Tümörleri
Synopsis
References
Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, Cleary SP, Hobday T, Halfdanarson TR. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist. 2022 Jul 05;27(7):573-578.
Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589.
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011 Mar 04;331(6021):1199-203.
Khanna L, Prasad SR, Sunnapwar A, Kondapaneni S, Dasyam A, Tammisetti VS, Salman U, Nazarullah A, Katabathina VS. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification. Radiographics. 2020 Sep-Oct;40(5):1240-1262.
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115–54.
Kasumova GG, Tabatabaie O, Eskander MF, et al. National Rise of Primary PancreaticCarcinoid Tumors: Comparison to Functional and Nonfunctional PancreaticNeuroendocrine Tumors. J Am Coll Surg 2017; 224:1057.
Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol. 2020 May 21;26(19):2305-2322.
Chiti G, Grazzini G, Cozzi D, Danti G, Matteuzzi B, Granata V, Pradella S, Recchia L, Brunese L, Miele V. Pankreas Nöroendokrin Neoplazmalarının Görüntülenmesi. Int J Çevre Res Halk Sağlığı. 24 Ağustos 2021; 18 (17)
You H, Kandathil A, Beg M, De Blanche L, Kazmi S, Subramaniam RM. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low, medium and high-grade neuroendocrine tumors. Nucl Med Communication 2020 October; 41 (10):1060-1065.
Marini F, Giusti F, Brandi ML. Genetic disorders and insulinoma/glucagonoma. Endocr Relat Cancer. May 2024, 01; 31 (5)
Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK. European Society of Neuroendocrine Tumors 2023 guidance document for functional pancreatic neuroendocrine tumor syndromes. J Neuroendocrinol. 2023 August; 35 (8):e13318.
Warren AM, Topliss DJ, Hamblin PS. Successful medical management of insulinoma with diazoxide for 27 years. Endocrinol Diabetes Metab Case Rep. 2020 06 Oct; 2020
Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the Patient: Insulinoma. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109-1118.
Chatzipanagiotou O, Schizas D, Vailas M, Tsoli M, Sakarellos P, Sotiropoulou M, Papalambros A, Felekouras E. All you need to know about gastrinoma today Gastrinoma and Zollinger-Ellison syndrome: A thorough update. J Neuroendocrinol. 2023 Apr;35(4):e13267.
Tobias J, Keutgen XM. Diagnostics and Imaging for Pancreatic Neuroendocrine Tumors. Surg Clin North Am. 2024 Aug;104(4):883-890.
Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res. 2004 Jul;120(1):139-61.
Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: statistical evaluation of 173 reported cases compared with other pancreatic endocrinomas. J Exp Clin Cancer Res. 1999 March; 18 (1):13-22.
Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E., Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018 Nov 01;4(11):1597-1604.
Williamson JM, Thorn CC, Spalding D, Williamson RC. Pancreatic and peripancreatic somatostatinomas. Ann R Coll Surg Engl. 2011 Jul;93(5):356-60.
de Herder WW, Hofland J. Glucagon & Glucagonoma Syndrome. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Apr 7, 2023.
John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022
Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, Mărginean O, Iacob ER, Iacob D, Motoc AGM, Boia ES. Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol. 2017;58(2):371-376.
Brugel M, Walter T, Goichot B, Smith D, Lepage C, Do Cao C, et al. Efficacy of treatments for VIPoma: A GTE multicentric series. Pancreatology. 2021;21(8):1531–9.
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153–71.
